Physician profile
Amanda Tuck
NPI 1720831563
$2,091.90
in general payments reported to CMS, 2019-2025
25 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $569 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.91 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $263.22 | 2024-2025 | Veozah |
| Lilly USA, LLC | $231.52 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $227.04 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $147.18 | 2024-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Amgen INC. | $142.76 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.09 | 2024-2025 | Jardiance, Synjardy |
| Abbvie INC. | $116.61 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.65 | 2025 | |
| Exact Sciences Corporation | $102.83 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $89.05 | 2024-2025 | Nexletol |
| Pfizer INC. | $74.34 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $71.97 | 2024-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $61.23 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.51 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $35.92 | 2025 | Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.65 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $33.51 | 2025 | Zoryve |
| Dexcom, INC. | $27.26 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $26.56 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $24.30 | 2024 | Eliquis |
| Abbott Laboratories | $24.10 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $22.87 | 2024 | Voquezna |
| Seqirus USA INC | $16.31 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $15.30 | 2025 | Minimed 780g |
| Corcept Therapeutics | $15.12 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Tuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.